Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 years
Pediatric Blood & Cancer2012Vol. 60(2), pp. 175–184
Citations Over TimeTop 10% of 2012 papers
Riccardo Haupt, Milen Minkov, Itziar Astigarraga, Eva Schäfer, Vasanta Nanduri, Rima Jubran, R. Maarten Egeler, Gritta Janka, Dragan Mićić, Carlos Rodríguez‐Galindo, Stefaan Van Gool, Johannes Visser, Sheila Weitzman, Jean Donadieu, for the Euro Histio Network
Abstract
These guidelines for the management of patients up to 18 years with Langerhans cell histiocytosis (LCH) have been set up by a group of experts involved in the Euro Histio Net project who participated in national or international studies and in peer reviewed publications. Existing guidelines were reviewed and changed where new evidence was available in the literature up to 2012. Data and publications have been ranked according to evidence based medicine and when there was a lack of published data, consensus between experts was sought. Guidelines for diagnosis, initial clinical work-up, and treatment and long-term follow-up of LCH patients are presented.
Related Papers
- → Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study(2018)33 cited
- → Imaging findings in Langerhans' cell histiocytosis of the liver and the spleen in an adult(1999)18 cited
- → [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].(2013)
- → Association of Langerhans Cell Histiocytosis with Erdheim-Chester Disease: How Close Monocyte/Macrophage and Dendritic Cell Lineages Are?(2010)